GeoVax Labs, Inc. (GOVX) stock
Close on Nov 11, 2026Market cap $821.67KP/E –Yield –
GeoVax Labs, Inc. saw revenue fall 100.0% to $0 over the twelve months to Jun 30, 2026. Free cash flow was -$18.37M. At the latest close the market valued the company at $821.67K.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $821.67K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.47
- Dividend yield
- –
- Free cash flow yield
- -2235.65%
Fundamentals
- Revenue
- $0
- Net income
- -$20.43M
- Free cash flow
- -$18.37M
- Book value per share
- $0.39
- Diluted shares
- 5M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $2.68
- Open
- $2.96
- Day's range
- $1.84 – $3.00
- Volume
- 518,230
- Average volume (20 days)
- 83,996
- Beta (5 years)
- 3.45
- 52-week range
- $0.11 – $13.00
- RSI (14 days)
- 13.0
- Volatility (1 year)
- 141.6%
- Relative volume
- 2.10×
- WACC
- 17.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GOVX | S&P 500 | Difference | GOVX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +668.7% | -2.4% | +671.1 pts | ||
| 3 months | -88.3% | -1.2% | −87.2 pts | ||
| Year to date | -49.5% | +12.3% | −61.8 pts | ||
| 1 year | -82.6% | +12.4% | −95.0 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -92.3% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -85.6% | +11.9% |
| 10 years | -99.6% | +311.1% | −410.7 pts | -42.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases GeoVax Labs filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- Results
- Update
- Results
- Results
About GeoVax Labs
Pharmaceutical Preparations
GeoVax Labs, Inc. is a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and solid tumors using novel proprietary platforms. The company's lead infectious disease candidate, GEO-MVA, targets mpox, smallpox, and other poxviruses, while its lead oncology program, Gedeptin, is a gene-directed enzyme prodrug therapy evaluated for advanced head and neck cancers. Additionally, the company develops GEO-CM04S1, a multi-antigen COVID-19 vaccine designed for immunocompromised individuals and booster applications, alongside preclinical vaccine programs targeting hemorrhagic fevers such as Ebola and Marburg viruses. GeoVax directs its solutions toward high-risk patient populations, healthcare providers, and public health or biodefense agencies.
Company profile, executives and historyGeoVax Labs stock: common questions
What is GeoVax Labs's stock price?
GOVX closed at $2.16 on Nov 11, 2026, down 19.28% on the day. Over the past 52 weeks it traded between $0.11 and $13.00.
What is GeoVax Labs's market cap?
GeoVax Labs was worth $821.67K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does GeoVax Labs make?
GeoVax Labs reported revenue of $0 for the twelve months to Jun 30, 2026, down 100.0% from a year earlier.
Does GeoVax Labs pay a dividend?
No. GeoVax Labs has not paid a cash dividend over the last twelve months.
When does GeoVax Labs report earnings next?
GeoVax Labs is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has GOVX stock performed over the past year?
Including dividends, GOVX returned -82.6% over the past year, against +12.4% for the S&P 500.
How many GOVX shares are sold short?
0M shares were sold short at the latest FINRA report, 2.45% of the float, or 1.0 days of average trading volume.
Who are GeoVax Labs's competitors?
Companies most similar to GeoVax Labs by business, industry and size include VCNX, NWBO, PVCT, MNOV, SXTP.
See a number that looks wrong?